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Abstract
Backgrounds: Pneumocystis jirovecii pneumonia (PCP) remains an important cause of morbidity and mortality in
kidney transplant recipients. While the acute phase toxicity in patients with PCP is well-characterized, there is a lack
of data on the effects of PCP on long-term graft outcome.
Method: This retrospective observational study analyzed 1502 adult patients who underwent kidney transplantation
at Seoul National University Hospital between 2000 and 2017. After a propensity score matching was performed,
the graft and survival outcomes were compared between PCP-negative and PCP-positive groups.
Results: A total of 68 patients (4.5%) developed PCP after transplantation. The multivariable Cox analysis showed
that positivity for cytomegalovirus and lack of initial oral antibiotic prophylaxis were risk factors of post-transplant
PCP. The PCP-positive group had higher hazard ratios of graft failure [adjusted hazard ratio (HR), 3.1 (1.14–8.26); P =
0.027] and mortality [adjusted HR, 11.0 (3.68–32.80); P < 0.001] than the PCP-negative group. However, the PCP
event was not related with subsequent development of de novo donor-specific antibodies or pathologic findings,
such as T-cell or antibody mediated rejection and interstitial fibrosis and tubular atrophy.
Conclusions: PCP is a risk factor of long-term graft failure and mortality, irrespective of rejection. Accordingly,
appropriate prophylaxis and treatment is needed to avoid adverse transplant outcomes of PCP.
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Background
With the continued development of immunosuppressive
regimens in the past decade, death-censored graft fail-
ures have gradually decreased in recipients of both living
and deceased kidney recipients [1, 2]. However, the mor-
tality rates in patients with functioning grafts remain un-
changed over the past 10 years [1, 2]. More information
on the causes of mortality unrelated to graft failure is
therefore needed to further improve the survival of
transplant recipients.
Infection is an important factor in relation to the risk
of death in kidney transplant recipients, and the second
most common cause of death after cardiovascular dis-
ease in patients with functioning grafts [3–5]. The inci-
dence of most infectious diseases, such as urinary tract
infection and sepsis, has been steadily maintained over
the past 15 years [6]. Despite its clinical implication of
these infectious diseases, there is little data on immuno-
logic outcomes after specific infectious disease in trans-
plant recipients. Further studies of post-transplant
infectious events are therefore needed to characterize
and ultimately improve survival outcomes.
Pneumocystis jirovecii is an opportunistic pathogen
that causes severe pulmonary infection in immunocom-
promized hosts [7]. The incidence of P. jirovecii pneu-
monia (PCP) varies from 0.6 to 14% among kidney
transplant recipients without prophylaxis, with a mortal-
ity of up to 50% despite aggressive antibiotic therapy [8,
9]. Several studies have investigated the relationship be-
tween PCP and mortality [9, 10], but the effect of PCP
on graft rejection and overall graft outcomes has been
less-well explored. Certain infections such as cyto-
megalovirus (CMV) and BK virus have demonstrated re-
lationships with acute rejection during the early
posttransplant period [11–14]. This is a meaningful clin-
ical issue, given that appropriate infection prophylaxis
and treatment regimens could be implemented to
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address subsequent immunological complications. How-
ever, the clinical implications of PCP have not yet been
resolved. Herein, we evaluated the impact of PCP on
kidney transplant outcomes, including graft failure and
rejection.
Methods
Study design and subjects
The study design was approved by the institutional re-
view board of Seoul National University Hospital (no. H-
1805-173-948) and complied with the Declaration of
Helsinki. This retrospective observational study included
total 1827 patients who had kidney transplantation at
Seoul National University Hospital from January 2000 to
December 2017. Patients who were under 18 years old
(n = 260) or who received simultaneous kidney–pancreas
or kidney–liver transplants (n = 65) were excluded. Con-
sequently, the remaining 1502 patients were finally in-
cluded and their data were reviewed. The requirement
of informed consent was waived by the board.
Data collection and definitions
Data from the kidney transplant recipients were col-
lected from the electronic medical records. Demographic
characteristics including age, gender, height, weight, and
body mass index were collected. Pre-transplant status,
including prior history of transplantation, the type and
duration of dialysis, history of diabetic nephropathy as a
cause of kidney failure, and comorbidities such as hyper-
tension and diabetes, was evaluated.
Results for both recipient and donor ABO blood
groups (ABO) and human leukocyte antigen (HLA)
typing were collected to evaluate ABO compatibility
and the number of HLA mismatches. Immunosup-
pressive therapy was determined, including induction
therapy with basiliximab or anti-thymocyte globulin,
and calcineurin inhibitors for maintenance therapy. A
combination of steroids, mycophenolic acid, and cal-
cineurin inhibitors was the standard maintenance im-
munosuppressive regimen in our center. PCP was
defined as the presence of findings suspicious of PCP
detected by a radiologist on chest computed tomog-
raphy combined with PCP positivity on polymerase
chain reaction or direct immunofluorescence stain of
sputum or bronchoalveolar lavage fluid. Initial use of
oral prophylactic antibiotics was defined as a pre-
scription of trimethoprim/sulfamethoxazole for more
than 4 weeks during the first month after kidney
transplantation. There were no cases with pentamidin
or atovaquon for prophylaxis. CMV positivity was de-
fined as > 20 copies/ml on polymerase chain reaction
or positive result on viral culture, according to the
definition of CMV infection [15].
Transplant outcomes
The primary outcome was death-censored graft failure
defined as a return to dialysis or kidney re-
transplantation. The secondary outcome was all-cause
mortality, based on data obtained from the National
Database of Statistics Korea. All patients were followed
until graft failure or March 2018. Data on biopsy-proven
acute T-cell-mediated rejection, acute antibody-mediated
rejection, and interstitial fibrosis and tubular atrophy
were also collected. Protocol biopsies were performed at
zero-time (postreperfusion), on the 10th day and 1 year
after transplantation, and every year thereafter. Add-
itional kidney biopsies were performed if graft function
deteriorated or any suspicious symptoms or signs of re-
jection were observed. All pathologic findings were ex-
amined by a nephropathologist. The development of de
novo donor-specific antibody (DSA) was defined as any
newly developed anti-HLA class I or II antibody.
Statistical analysis
All statistical analyses were performed using Stata soft-
ware (version 15.1, StataCorp, College Station, TX, USA)
. Data are expressed as mean ± standard deviation for
continuous variables or counts with percentages for cat-
egorical variables. Among the baseline characteristics,
categorical variables were compared using χ2 and Fish-
er’s exact tests and continuous variables were compared
using Student’s t-test. Risk factors for PCP occurrence
were analyzed using univariable and multivariable Cox
proportional hazard models.
Propensity score matching was performed to ac-
count for the imbalance in baseline characteristics be-
tween the PCP-positive and -negative groups. Scores
were created with matching variables including age,
gender, donor type, type of pre-transplant dialysis,
hypertension, the usage of prophylactic antibiotics,
and CMV positivity which had P values under 0.1 in
multivariable Cox analysis for the risk of PCP. Then,
the cases were matched on propensity score in a 1:2
block, using a nearest neighbor matching algorithm
with replacement, using the statistical package
psmatch2. Following propensity score matching, graft
survival, overall patient survival, risk of rejection and
development of DSA were analyzed using univariable
and multivariable Cox proportional hazard models.
Because PCP infection was a time-dependent covari-
ant in the Cox model, we used the stssplit function
in Stata to split the time at which PCP occurred. The
proportionality assumption was checked for propor-
tional hazard Cox regression. Survival curves were
drawn using the Kaplan–Meier method, with compar-
isons between groups carried out using the log-rank
test. A P value < 0.05 was considered to indicate stat-
istical significance.
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Results
Baseline characteristics and risk factor of PCP
Table 1 shows the demographic and clinical characteris-
tics of the total study subjects, according to the PCP sta-
tus. The median duration of follow-up was 6.2 years
(interquartile range, 3.0–9.6 years; maximum 18.3 years).
Of the 1502 patients, 68 (4.5%) experienced PCP after
kidney transplantation, with an infection rate of 6.8 cases
per 1000 person-years. The median time to the develop-
ment of PCP was 5.2 months (interquartile range, 3.9–
10.0 months), and 79.4% of cases developed during the
first year after transplantation. There were significant
differences between PCP-positive and -negative patients
with respect to gender, type of pre-transplant dialysis,
ABO-incompatibility, desensitization therapy, induction
regimen, hypertension and CMV positivity. After adjust-
ment for multiple covariates, CMV positivity and the
non-use of oral prophylactic antibiotics were associated
with an increased risk of PCP (Table 2).
PCP and transplant outcomes
We performed propensity score matching to mitigate
the difference in baseline characteristics between the
PCP-positive and -negative groups. Table 3 shows the
baseline characteristics of the two groups of patients
after propensity score matching. Among 68 PCP-positive
recipients, 9 (13.2%) patients developed death-censored
graft failure. Figure 1 shows the Kaplan-Meier curves for
death-censored graft survival, and the curves were sepa-
rated by the presence of PCP (P = 0.008). Cox regression
analysis considering PCP as a time-dependent variable
was subsequently performed. Both univariable and mul-
tivariable analyses showed a significant relationship be-
tween PCP and graft failure, with HRs of 3.34 (1.31–
8.56) (P = 0.012) and 3.33 (1.30–8.53) (P = 0.012), re-
spectively. Although the acute T cell-mediated and
antibody-mediated rejection episodes or other immuno-
logical findings such as interstitial fibrosis and tubular
atrophy and de novo DSA were additionally adjusted,
the PCP-positive recipients had a higher risk of death-
censored graft failure than the PCP-negative recipients
(adjusted HR, 3.06 [1.14–8.26]); P = 0.027).
The clinical information on the PCP-positive patients
with graft failure (n = 9) are shown in Additional file 1:
Table S1. All the patients were male and had no history
of prophylactic antibiotics usage after transplantation.
During the admission period, 8 of 9 patients (88.9%) ex-
perienced acute kidney injury according to the Kidney
Disease Improving Global Outcomes criteria [16], and 4
of them (50%) did not have recovered their graft func-
tions at discharge despite the recovery from PCP. To de-
termine the cause of the elevated risk of graft failure, we
evaluated the effect of PCP on the risk of subsequent oc-
currence of rejection, interstitial fibrosis and tubular











Age (years) 45.3 ±
13.0
45.1 ± 13.0 48.3 ± 14.4 0.053
Female (%) 39.1 39.9 23.5 0.007
Body mass index (kg/m2) 22.5 ±
3.7
22.5 ± 3.8 22.6 ± 2.6 0.969
Donor type (%) 0.124
Living 67.4 67.8 58.8







Pre-transplant dialysis (%) 0.005
Preemptive 15.6 15.3 22.1
Hemodialysis 65.2 66.0 47.1





40.0 ± 47.5 42.9 ± 51.9 0.650
Re-transplantation 7.2 7.2 7.4 0.958
ABO-incompatible (%) 7.4 6.8 19.1 <
0.001
HLA mismatch (numbers) 3.1 ± 1.7 3.1 ± 1.7 3.1 ± 1.7 0.983
HLA-A 0.9 ± 0.7 0.9 ± 0.7 1.0 ± 0.8 0.344
HLA-B 1.2 ± 0.7 1.2 ± 0.7 1.2 ± 0.8 0.861
HLA-DR 1.0 ± 0.7 1.0 ± 0.7 0.9 ± 0.7 0.291
Calcineurin inhibitor (%) 0.260
None 3.1 3.0 5.9
Cyclosporine 13.0 13.2 8.8
Tacrolimus 83.9 83.8 85.3
mTOR inhibitor (%) 1.9 1.9 2.9 0.535
Induction regimen (%) 0.022
None 19.0 19.6 7.4
Basliximab 79.6 78.9 92.6
Antithymocyte globulin 1.4 1.5 0
Desensitization (%) 11.5 10.9 22.1 0.005
Diabetes mellitus (%) 19.0 18.9 22.1 0.517
Hypertension (%) 89.9 89.5 98.5 0.016
DMN for kidney failure (%) 16.4 16.3 19.1 0.543




18.8 19.2 10.3 0.067
Comparisons were evaluated between PCP-negative and PCP-positive groups
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HLA human leukocyte
antigen, DMN diabetic nephropathy, mTOR mammalian target of rapamycin,
CMV cytomegalovirus
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atrophy, and de novo DSAs. However, these outcomes
did not differ between PCP-positive and –negative
groups (Table 4). The results suggest that different graft
failure rates might not be attributable to the conven-
tional immunological transplant episodes, but might be
related with non-immunological factors such as concur-
rent acute kidney injury.
During the follow-up period, 11 patients (16.2%) and
13 patients (11.0%) died in the PCP-positive and
-negative groups, respectively. The 28 PCP-positive pa-
tients had concurrent other infectious diseases, and 8
patients died (28.6%). All-cause mortality was higher in
the PCP-positive group than in the PCP-negative group
(Fig. 2). The PCP-positive group had a higher risk of
Table 2 Risk factors for PCP occurrence after kidney
transplantation
Variables Univariable Multivariable*
HR (95% CI) P HR (95% CI) P
Age 1.02 (1.00–1.04) 0.015 stratified
Female 0.46 (0.27–0.81) 0.007 0.56 (0.30–1.06) 0.074
Body mass index 1.01 (0.95–1.08) 0.761
Donor type
Living donor 1 (reference) 1 (reference)
Standard criteria donor 1.43 (0.83–2.46) 0.194 1.89 (0.91–3.94) 0.090
Expanded criteria donor 2.22 (1.03–4.77) 0.041 1.14 (0.37–3.50) 0.818
Pre-transplant dialysis
Preemptive 1 (reference) 1 (reference)
Hemodialysis 0.51 (0.28–0.95) 0.033 0.42 (0.19–0.89) 0.023
Peritoneal dialysis 1.10 (0.57–2.13) 0.786 0.91 (0.39–2.11) 0.829
Duration of dialysis 1.00 (1.00–1.01) 0.464
Re-transplantation 1.03 (0.41–2.56) 0.948
ABO-incompatible 3.75 (2.13–6.93) <
0.001
1.60 (0.38–6.77) 0.521
HLA mismatch (numbers) 1.02 (0.88–1.17) 0.834
Calcineurin inhibitor
None 1 (reference) 1 (reference)
Cyclosporine 0.27 (0.08–0.97) 0.045 0.34 (0.07–1.65) 0.179






Antithymocyte globulin NE NE
Desensitization 2.67 (1.49–4.76) 0.001 2.67 (0.66–
10.76)
0.167






DMN for kidney failure 1.32 (0.72–2.41) 0.373




4.48 (2.58–7.79) < 0.001
Oral prophylactic
antibiotics
0.54 (0.25–1.19) 0.129 0.35 (0.15–0.82) 0.016
*Adjusted for gender, donor type, ABO compatibility, desensitization,
hypertension, positivity of CMV and oral prophylactic antibiotics. Because age
and induction regimen violated the proportionality assumption, multivariable
Cox model was stratified by age and induction regimen
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HR hazard ratio, CI
confidence interval, HLA human leukocyte antigen, NE not estimable, DMN
diabetic nephropathy, CMV cytomegalovirus








Age (years) 46.7 ± 14.6 48.3 ± 14.4 0.504
Female (%) 21.8 23.5 0.792
Body mass index (kg/m2) 22.5 ± 3.4 22.6 ± 2.6 0.509
Donor type (%) 0.447
Living 64.5 58.8
Deceased 35.5 41.2 0.846
Standard criteria donor 24.5 29.4
Expanded criteria donor 10.9 11.8
Pre-transplant dialysis (%) 0.102
Preemptive 15.3 22.1
Hemodialysis 68.6 47.1
Peritoneal dialysis 16.1 30.9
Duration of dialysis (months) 47.4 ± 52.1 44.1 ± 54.0 0.704
Re-transplantation 6.8 7.4 0.883
ABO-incompatible (%) 7.6 19.1 0.019
HLA mismatch (numbers) 3.1 ± 1.5 3.1 ± 1.7 0.915




Induction regimen (%) 0.108
None 15.3 7.4
Basliximab 82.2 92.6
Antithymocyte globulin 2.5 0
Desensitization (%) 11.0 22.1 0.043
Diabetes mellitus (%) 20.3 22.1 0.781
Hypertension (%) 94.1 98.5 0.149
DMN for kidney failure (%) 19.5 19.1 0.950
Positivity for CMV (%) 57.6 60.3 0.722
Oral prophylactic antibiotics (%) 14.4 10.3 0.420




Interstitial fibrosis and tubular atrophy
(%)
37.3 42.6 0.471
De novo donor-specific antibody (%) 12.7 11.8 0.850
Comparisons were evaluated between PCP-negative and PCP-positive groups
Abbreviations: PCP Pneumocystis jirovecii pneumonia, HLA human leukocyte
antigen, DMN diabetic nephropathy, CMV cytomegalovirus
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mortality [adjusted HR, 10.99 (3.68–32.80); P < 0.001]
than the PCP-negative group.
Additional file 1 Table S2 lists the PCP-positive pa-
tients who died. Nine of Eleven patients (81.8%) died
within 3 months after the occurrence of PCP. The most
common cause of death was acute respiratory distress
syndrome related with PCP.
Discussion
Pneumocystis jirovecii is an ascomycetous fungus that
causes opportunistic infections, and its life cycle remains
unknown because it cannot be consistently cultured [17,
18]. Furthermore, the epidemiology of human PCP is un-
clear yet [17, 19]. Due to little knowledge about Pneumo-
cystis jirovecii, it is necessary to investigate whether the
long term effect of PCP on allografts is due to the infec-
tion alone or with chronic inflammatory process and other
unknown mechanisms. Although PCP is relatively com-
mon after kidney transplantation, its clinical implications,
especially in relation to graft outcomes, have not been
fully evaluated. The results of the present study demon-
strated that male gender and CMV positivity were risk
factors associated with PCP, and the use of oral prophylac-
tic antibiotics seemed to prevent the risk of PCP. The oc-
currence of PCP increased the risk of long-term graft
failure; however, this relationship was not dependent of re-
jection, interstitial fibrosis and tubular atrophy, or de novo
DSAs. Because PCP was associated with both graft failure
and overall mortality, intensive treatment and prophylaxis
is recommended after transplantation.
Previous studies have shown that CMV infection in-
creases a risk of PCP [20–22], as supported by the
present results. This may be because CMV might modify
the host immune response, leading to immune suppres-
sion [23, 24]. CMV infection affects the T cell compart-
ment and accelerates aging of T cells [25]. T-cells,
especially CD4 T cells, are important factors affecting
the vulnerability to and resolution of PCP [26], and al-
teration of the T cell response by CMV might aggravate
pulmonary impairment during PCP activation [27].
Pre-transplant dialysis was newly identified as a pro-
tective factor of PCP. None of previous studies have in-
cluded this factor in the analysis models. Uremic
condition is linked to altered immunological responses
Fig. 1 Overall graft survival curves in the PCP-positive and -negative patients. P value was obtained using the log-rank test. Dashed line, PCP-
positive; solid line, PCP-negative
Table 4 Risk of rejection and development of de novo donor-specific antibody according to the occurrence of PCP
Outcomes Univariable Multivariable*
HR (95% CI) P HR (95% CI) P
T-cell mediated rejection 0.49 (0.19–1.26) 0.140 0.50 (0.19–1.28) 0.148
Antibody mediated rejection 0.70 (0.15–3.27) 0.651 0.66 (0.14–3.08) 0.597
Interstitial fibrosis and tubular atrophy 1.51 (0.72–3.15) 0.274 1.62 (0.77–3.41) 0.204
De novo donor specific antibody 0.87 (0.28–2.66) 0.801 0.88 (0.29–2.70) 0.821
*Adjusted for variables which had P values less than 0.1 in Table 3
Abbreviations: HR hazard ratio, CI confidence interval
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[28]. Accordingly, appropriate pre-transplant resolution of
uremia would decrease the risk of post-transplant PCP.
However, a long-term pre-transplant dialysis negatively af-
fects the host immune status [29]. Additionally, other de-
tailed information such as the dose or adequacy of dialysis
which the present study did not obtain could function as
an interacting factor. Further studies are needed to deter-
mine the underlying mechanisms of above relationship.
The occurrence of PCP itself did not affect the risk of
following development of acute rejection and de novo
DSA production. Nevertheless, occurrence of PCP was
significantly associated with overall graft failure. As has
been previously demonstrated, viral infections such as
CMV, BK virus, and hepatitis C virus, and certain bacter-
ial infections such as Pseudomonas aeruginosa, affect
allograft dysfunction by modulating non-immunological
factors such as hemodynamic change in addition to im-
munological factors [30, 31]. In our results, PCP did not
increase the risk of any rejection after infection, suggest-
ing that non-immunological factors may be the cause
underlying the observations. Certain PCP-positive pa-
tients had concurrent acute kidney injury and half of
them did not achieve the recovery from this condition,
which might leave the grafts with non-immunological
damages. However, through non-immunological path-
ways, infections may also induce allograft injury by
stimulating the production of proinflammatory cytokines
such as interleukin-1, interleukin-6, and interleukin-8
[32]. These proinflammatory cytokines are known to be
upregulated in patients with PCP [26].
Mortality risk was elevated in patients with PCP. Nine
out of eleven (81.8%) patients died within 3months after
diagnosis of PCP infection. The causes of death in these
patients were either PCP itself or the other infection
superimposed on PCP. Thus, considering both the signifi-
cant effect of PCP on mortality and the negative effect on
graft outcome over long-term period, prophylaxis against
PCP may be strongly recommended. According to the
Kidney Disease Improving Global Outcomes guideline, it
is recommended that all recipients receive prophylaxis
against PCP for 3–6months after transplantation [33].
However, definitive guidelines on the duration and dosage
of PCP prophylaxis are not available and more research is
needed to determine the appropriate approach [33].
Although our data are informative, there are some lim-
itations. First, it was a retrospective study, making it dif-
ficult to demonstrate cause and effect definitively.
Nevertheless, the study achieved its primary purpose by
demonstrating the relationship between PCP and trans-
plant outcomes. Second, the current definition of
prophylactic antibiotics was 1 month, which was shorter
than the guideline recommendation (i.e., 3–6months),
which might increase overall risk of PCP in study sub-
jects. The duration of antibiotic prophylaxis (i.e., more
than 4 weeks) might differ between centers, which could
also alter the risk of PCP or other transplant outcomes.
However, this did not hinder the study purpose on the
relationship between PCP and transplant outcomes.
Lastly, the present observational study design could not
determine the mechanisms underlying the risk and sub-
sequent effect of PCP.
Conclusion
Risk of PCP is aggravated in the kidney transplant cases
with male gender, positivity for CMV, and non-use of
oral prophylactic antibiotics. PCP significantly increases
Fig. 2 Patient survival curves in the PCP-positive and -negative patients. P value was obtained using the log-rank test. Dashed line, PCP-positive;
solid line, PCP-negative
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both the risks of mortality and graft failure. Accordingly,
robust prophylaxis may be needed to prevent PCP and
subsequent graft failure. The present results will be the
basis of the future clinical trials on the use of prophy-
laxis in kidney transplant recipients.
Additional files
Additional file 1: Table S1. Information on the patients who had graft
loss after the occurrence of Pneumocystis jirovecii pneumonia. Table S2.
Information on the patients who died after the diagnosis of Pneumocystis
jirovecii pneumonia. (DOCX 20 kb)
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CI: Confidence interval; CKD: Chronic kidney disease; CMV: Cytomegalovirus;
DMN: Diabetic nephropathy; DSA: Donor-specific antibody; HLA: Human
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